An investigation on behalf of investors in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was announced over potential breaches of fiduciary duties by certain officers and directors at Sunesis Pharmaceuticals, Inc.
Investors who purchased shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On May 2, 2017, Sunesis Pharmaceuticals, Inc. announced that it will withdraw its European Marketing Authorization Application for vosaroxin, its proposed treatment for relapsed/refractory AML. Sunesis Pharmaceuticals, Inc. conveyed to shareholders that its decision followed recent interactions with the European Medicine Agency’s Committee for Medicinal Products for Human Use, in which it learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product. Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) declined on May 3, 2017 to $2.82 per share.
On May 22, 2017, NASDAQ:SNS shares closed at $3.19 per share.
Those who purchased NASDAQ:SNSS shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego